Increased intestinal permeability can represent compromise of the epithelium's integrity and is thought to be the primary mechanism in patients who develop Celiac Disease (CeD) and non-celiac gluten sensitivity when gluten peptides cross the barrier and trigger an immune response. In this study, the investigators propose to use a novel, minimally invasive technology to detect mucosal damage (i.e. barrier dysfunction) in the duodenal epithelium. The primary aim of this study is to identify if there is a difference in duodenal mucosal impedance between CeD and control patients.
Study Type
OBSERVATIONAL
Enrollment
33
During routine endoscopy, consented study participants will have a mucosal impedance catheter sensor positioned along the mucosal wall to measure resistance across the mucosa. The study procedure will add approximately 1-2 minutes of anesthesia time for each participant.
At time of endoscopy, subjects with initial positive CeD serology will have a blood sample taken for any missing CeD serologies and intestinal fatty acid-binding protein (IFABP). This will be done at time of IV initiation as to avoid any additional venipuncture.
Vanderbilt University Medical Center Endoscopy Laboratory
Nashville, Tennessee, United States
mucosal impedance values
Identify if there is a difference in duodenal mucosal impedance between CeD and control patients
Time frame: Values will be obtained at conclusion of esophagogastroduodenoscopy (EGD), an expected average of 6 minutes
Marsh Score
Correlate measures of duodenal impedance with standardized pathology scores in CeD (Marsh Score)
Time frame: 1 week
IFABP
Identify whether there is a difference in IFABP in patients with normal and abnormal mucosal impedance
Time frame: 1 week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.